Latest Breaking News On - Ted effector - Page 1 : comparemela.com

DGAP-News: CatalYm GmbH: CatalYm to Present Initial Data of First-in-Human Trial of GDF-15 neutralizing antibody CTL-002 at the 2021 ASCO Annual Meeting The poster A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced-stage solid tumors (ACRONYM: GDFATHER) , Abstract TPS2658 , will present CatalYm s first-in-human, two-part, open-label phase 1 clinical trial of CTL-002, a neutralizing antibody targeting GDF-15. GDF-15 is a factor that is secreted by several major tumor entities and interferes with effector T cell recruitment. In the GDFATHER-trial, patients with advanced-stage, solid tumors who have not responded or stopped responding to anti-PD-1/PD-L1 therapy are treated with CTL-002 as monotherapy and followed by combination with an anti-PD-1 antibody. The first patient was enrolled in December 2020.

United statesChristine schuberth wagnerKatja arnoldWachstumsfonds bayernPhil lhuilierShaun brownKostenloser wertpapierhandelCatalym gmbPhil lhuillierJoerg wischhusenMc servicesEuropean unionEuropean fund for strategic investmentsNovartis venture fundDistribution servicesCatalym gmbh